Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Prostate cancer incidences are rising worldwide at an alarming rate. Drug resistance and relapse are two major challenges in the treatment of prostate cancer. Therefore, new multimodal, safe, and effective therapeutic agents are urgently required which could effectively mitigate the menace of tumor recurrence and chemo-resistance. Plant-derived products are increasingly being utilized due to their antioxidant, antibacterial, and anti-tumor potential. In the current study, 3-acetyl-11-keto-β-boswellic acid, a triterpenoid isolated from plant Boswellia, was utilized to ascertain its chemotherapeutic potential against human prostate cancer cells. Various in vitro assays including cell viability, nuclear staining, mitochondria potential, reactive oxygen species (ROS) generation, and quantification of apoptosis, were performed for the evaluation of the cytotoxic potential of AKBA. We observed that AKBA (10-50 µM) dose-dependently suppressed cell proliferation and caused programmed cell death in PC3 cells via both intrinsic and extrinsic pathway. Intriguingly, AKBA was also found to chemosensitize PC3 cells in synergistic combination with doxorubicin. To the best of our knowledge, this is the first study to document the synergistic chemosensitizing impact of AKBA when combined with doxorubicin in prostate cancer cells.This showcases the potential of AKBA in combinatorial therapy or adjuvant therapy for the management of prostate cancer. In sum, our results suggested that AKBA is a promising drug-like molecule against prostate cancer. Our investigation introduces a novel perspective, elucidating a previously unexplored dimension, and uncovering a compelling chemosensitizing phenomenon along with a strong synergistic effect arising from the concurrent application of these two agents.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Molecular biotechnology - (2024) vom: 19. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Verma, Mahima [VerfasserIn] |
---|
Links: |
---|
Themen: |
3-acetyl-11-keto-β-boswellic acid |
---|
Anmerkungen: |
Date Revised 19.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1007/s12033-024-01089-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369920635 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM369920635 | ||
003 | DE-627 | ||
005 | 20240320235125.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240320s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12033-024-01089-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1337.xml |
035 | |a (DE-627)NLM369920635 | ||
035 | |a (NLM)38502429 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Verma, Mahima |e verfasserin |4 aut | |
245 | 1 | 0 | |a Anti-proliferative, Pro-apoptotic, and Chemosensitizing Potential of 3-Acetyl-11-keto-β-boswellic Acid (AKBA) Against Prostate Cancer Cells |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 19.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
520 | |a Prostate cancer incidences are rising worldwide at an alarming rate. Drug resistance and relapse are two major challenges in the treatment of prostate cancer. Therefore, new multimodal, safe, and effective therapeutic agents are urgently required which could effectively mitigate the menace of tumor recurrence and chemo-resistance. Plant-derived products are increasingly being utilized due to their antioxidant, antibacterial, and anti-tumor potential. In the current study, 3-acetyl-11-keto-β-boswellic acid, a triterpenoid isolated from plant Boswellia, was utilized to ascertain its chemotherapeutic potential against human prostate cancer cells. Various in vitro assays including cell viability, nuclear staining, mitochondria potential, reactive oxygen species (ROS) generation, and quantification of apoptosis, were performed for the evaluation of the cytotoxic potential of AKBA. We observed that AKBA (10-50 µM) dose-dependently suppressed cell proliferation and caused programmed cell death in PC3 cells via both intrinsic and extrinsic pathway. Intriguingly, AKBA was also found to chemosensitize PC3 cells in synergistic combination with doxorubicin. To the best of our knowledge, this is the first study to document the synergistic chemosensitizing impact of AKBA when combined with doxorubicin in prostate cancer cells.This showcases the potential of AKBA in combinatorial therapy or adjuvant therapy for the management of prostate cancer. In sum, our results suggested that AKBA is a promising drug-like molecule against prostate cancer. Our investigation introduces a novel perspective, elucidating a previously unexplored dimension, and uncovering a compelling chemosensitizing phenomenon along with a strong synergistic effect arising from the concurrent application of these two agents | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a 3-acetyl-11-keto-β-boswellic acid | |
650 | 4 | |a Boswellia serrata | |
650 | 4 | |a Chemo-sensitization | |
650 | 4 | |a Doxorubicin | |
650 | 4 | |a Prostate cancer | |
700 | 1 | |a Fatima, Shireen |e verfasserin |4 aut | |
700 | 1 | |a Saeed, Mohd |e verfasserin |4 aut | |
700 | 1 | |a Ansari, Irfan Ahmad |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Molecular biotechnology |d 1994 |g (2024) vom: 19. März |w (DE-627)NLM075082349 |x 1559-0305 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:19 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12033-024-01089-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 19 |c 03 |